JPRN-jRCTs031180104已完成2 期
Phase II study investigating efficacy and safety of TFTD plus bevacizumab by RAS mutation status in patients with unresectable advanced or recurrent colorectal cancer refractory or intolerant to standard chemotherapy(JFMC51-1702-C7) - JFMC51-1702-C7
Takahashi Takao0 个研究点目标入组 102 人开始时间: 2019年2月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 102
研究概览
简要总结
Among 102 enrolled patients, 97 patients fulfilled the eligibility criteria (48 in the RAS WT cohort and 49 in the RAS MUT cohort). DCRs in the RAS WT and MUT cohort were 66.7% (P =0.0013) and 55.1% (P = 0.0780), respectively. The median PFS and OS were 3.8 and 9.3 months, respectively in the RAS WT cohort, 3.5 and 8.4 months, respectively in the RAS MUT cohort. The most common grade 3 or higher adverse event in both cohorts was neutropenia (46% in the RAS WT cohort and 62% in the RAS MUT cohort).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Histologically confirmed advanced or recurrent colorectal adenocarcinoma (exclude appendix and anal cancer)
- •2.Unresectable colorectal cancer confirmed by imaging
- •3.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •4.Confirmed RAS mutation status
- •5.Treatment history of one or more regimens of standard chemotherapy
- •(1) Refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, angiogenesis inhibitor (bevacizumab, ramucirumab, or aflibercept), and anti-EGFR antibody (cetuximab or panitumumab) for wild-type RAS
- •(2) Exclude history of intolerance to bevacizumab
- •(3)Include history of adjuvant chemotherapy if a tumor had relapsed within 6 months after the last administration
- •6 No treatment history of regorafenib and TFTD
- •7.Measurable lesions based on the Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) within the 21 days before enrolment
- •8.Adequate bone marrow, hepatic, and renal functions
- •9.Written informed consent
排除标准
- •1.History of intolerance to bevacizumab
- •2.Thromboembolic events within the 6 months before enrolment
- •3.Active bleeding
- •4.Severe heart disease within the 6 months before enrolment
- •5.Cerebrovascular events
- •6.Active infections
- •7.Ascites, pleural effusion, or pericardial effusion requiring treatment
- •8.Gastrointestinal obstruction, renal failure, or liver failure
- •9.Uncontrolled diabetes mellitus
- •10.Uncontrolled hypertension
- •11.Positive for Hepatitis B surface antigen (HbsAg+) or Hepatitis C antibody (HCV Ab+)
- •12.Other active cancer
- •13.Symptomatic brain metastases
- •14.Requiring immunosuppressive treatment due to an autoimmune disorder or history of organ transplantation
- •15.Treatment history;
- •(1)Major surgery (i.e., thoracotomy or laparotomy) within the 4 weeks before enrollment
- •(2)Chemotherapy within the 2 weeks before enrollment
- •(3)Extensive exposure of radiation within the 4 weeks before enrollment
- •16.Unresolved adverse events of grade 2 or higher (classified with the National Cancer Institute Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) from previous treatment
- •17.Unhealed wound or traumatic fracture
- •18.tendency of haemorrhage and undergoing treatment with an antithrombotic drug (including a daily dose of 325 mg or more of oral aspirin)
- •19.Females who are in pregnancy, breastfeeding, with a positive pregnancy test or unwilling to use adequate contraception or males of reproductive potential
- •20.Clinically significant mental or psychological disorder
- •21.Patients whose participation in the trial was judged to be inappropriate by the investigator
研究者
相似试验
已完成
2 期
A randomized phase II study of daily administrations versus alternate-day administrations of TS-1 for the elderly patient with completely resected pathological stage IA(T1bN0M0)-IIIA of non-small cell lung canceron Small Cell Lung CancerJPRN-UMIN000007819Setouchi Lung Cancer Group101
已完成
不适用
Phase II Study to Evaluate Efficacy and Safety of Capecitabine + Cisplatin Combination Therapy in Gastric Cancer Patients Who Relapsed After S-1 Adjuvant ChemotherapyGastric CancerJPRN-UMIN000005857Epidemiological and Clinical Research Information Network (ECRIN)40
已完成
2 期
Phase 2 study evaluating the efficacy and safety of the combination of Bendamustine, Rituximab and Dexamethazone (RBenda-D) for treatment of CD20-positive relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.JPRN-UMIN000008145Kyoto Prefectural University of Medicine/K-LSG33
已完成
2 期
A phase II study to confirm the feasibility of S-1 plus CPT-11 as a post operative chemotherapy for the patients with advanced gastric cancer in stage IIIA and IIIB (OGSG 0801)JPRN-UMIN000002181Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)53
进行中（未招募）
2 期
Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsNon-small Cell Lung CancerNCT05801107Qilu Pharmaceutical Co., Ltd.30